[{"id":"000be60f-42db-41e6-b058-9c726c67adee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05636215","created_at":"2022-12-05T16:57:09.199Z","updated_at":"2024-07-02T16:35:59.279Z","phase":"Phase 1/2","brief_title":"A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors","source_id_and_acronym":"NCT05636215","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IBI-354"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 444","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 10/15/2024","primary_completion_date":" 10/15/2024","study_txt":" Completion: 07/15/2025","study_completion_date":" 07/15/2025","last_update_posted":"2022-12-12"}]